Understanding themechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: Insights from Bartter's and Gitelman's syndromes, humanmodels of endogenous angiotensin II signaling antagonism

Journal of Hypertension

Volumn 32, Issue 11, 2014, Pages 2109-2119

  Calò, Lorenzo A ^a   Davis, Paul A ^b   Rossi, Gian Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin II signaling; Cardiovascular remodeling; G protein; Hypertension; Nitric oxide; Oxidative stress; RGS 2; Rho kinase

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; CYCLIC AMP; CYCLIC GMP; GLUCOSE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL TRISPHOSPHATE; INSULIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM CHANNEL; PROTEIN TYROSINE KINASE; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR; RHO KINASE; TRANSFORMING GROWTH FACTOR BETA; GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

BARTTER SYNDROME; BLOOD VESSEL TONE; CARDIOVASCULAR FUNCTION; CELL PROLIFERATION; CLINICAL FEATURE; GAIN OF FUNCTION MUTATION; GITELMAN SYNDROME; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; KIDNEY FUNCTION; LOSS OF FUNCTION MUTATION; MUSCLE WEAKNESS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECOND MESSENGER; SENSITIZATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; UPREGULATION; METABOLISM;

ANGIOTENSIN II; BARTTER SYNDROME; GITELMAN SYNDROME; GLUCOSE; GTP-BINDING PROTEINS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84927667735     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000321     Document Type: Review

References (119)

1. Bartter FC, Pronove P, Gill JR, Maccardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. Am J Med 1962; 33:811-828.
2. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 1996; 13:183-188.
3. Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, et al. Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet 1996; 14:152-156.
4. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, et al. Mutation in the chloride channel geneCLCNKB, cause Bartter's syndrome type III. Nat Genet 1997; 17:171-179.
5. Hebert SC. Bartter syndrome. Curr Opin Nephrol Hypertens 2003; 12:527-532.
6. Gamba G. Molecular physiology and pathophysiology of electroneutral cation-chloride cotransporters. Physiol Rev 2005; 85:423-493.
7. Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Phys 1966; 79:221-235.
8. Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D. Bartter's and Gitelman's syndromes: from gene to clinic. Nephron Physiol 2004; 96:65-78.
9. Simon DB, Nelson-Williams C, Bia M, Ellison D, Karet FE, Molina AM, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996; 12:24-30.
10. Vargas-Poussou R, Dahan K, Kahila D, Venisse A, Riveira-Munoz E, Debaix H, et al. Spectrum of mutations in Gitelman's syndrome. J Am Soc Nephrol 2011; 22:693-703.
11. Bettinelli A, Tosetto C, Colussi G, Tommasini G, Edefonti A, Bianchetti MG. Electrocardiogram with prolonged QT interval in Gitelman disease. Kidney Int 2002; 62:580-584.
12. Scognamiglio R, Semplicini A, Calò LA. Myocardial function in Bartter's and Gitelman's syndromes. Kidney Int 2003; 64:366-367.
13. Scognamiglio R, Calò LA, Negut C, Coccato M, Mormino P, Pessina AC. Myocardial perfusion defects in Bartter and Gitelman syndromes. Eur J Clin Invest 2008; 38:888-895.
14. Favero M, Calò LA, Schiavon F, Punzi L. Bartter's and Gitelman's syndromes. Best Pract Res Clin Rheumatol 2011; 25:637-648.
15. Calò LA, Pessina AC, Semplicini A. Angiotensin II signaling in the Bartter's and Gitelman's syndromes, a negative humanmodel of hypertension. High Blood Press Cardiovasc Prev 2005; 12:17-26.
16. Calò LA. Vascular tone control in humans: insights from studies in Bartter's/Gitelman's syndromes. Kidney Int 2006; 69:963-966.
17. Mehta PK, Griendling KK. Angiotensin II cell signaling. Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 92:C82-C97.
18. Nguyen Dinh Cat A, Touyz RM. Cell signaling of angiotensin II on vascular tone: novel mechanisms. Curr Hypertens Rep 2011; 13:122-128.
19. Dzau VJ, Lopez-Ilasaca M. Searching for transcriptional regulators of Ang II induced vascular pathology. J Clin Invest 2005; 115:2319-2322.
20. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009; 119:524-530.
21. Calò L, D'Angelo A, Cantaro S, Rizzolo M, Favaro S, Antonello A, et al. Intracellular calcium signalling and vascular reactivity in Bartter's syndrome. Nephron 1996; 72:570-573.
22. Calò LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D'Angelo A, et al. Angiotensin II signalingvia type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hypertens 2010; 28:111-118.
23. Pedersen E, Brakebusch C. Rho GTPase function in development: how in vivo models change our view. Exp Cell Res 2012; 318:1779-1787.
24. Nguyen Dinh Cat A, Touyz RM. A new look at the renin-angiotensin system-focusing on the vascular system. Peptides 2011; 32:2141-2150.
25. Crowley SD, Coffman TM. Recent advances involving the renin-angiotensin system. Exp Cell Res 2012; 318:1049-1056.
26. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993; 361:315-325.
27. Davis Mj, Hill MH. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999; 70:387-423.
28. Moncada S, Higgs A. The L-Arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012.
29. Clementi E. Role of nitric oxide and its intracellular signalling pathways in the control of Ca2+ homeostasis. Biochem Pharmacol 1998; 55:713-718.
30. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease. A unifying hypothesis. Hypertension 2001; 37:1047-1052.
31. Calò LA, Pessina AC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens 2007; 25:259-264.
32. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G-proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83:1325-1358.
33. Sward K, Mita M, Wilson DP, Deng JT, Susnjar M, Walsh MP. The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction. Curr Hypertens Rep 2003; 5:66-72.
34. Mironneau J, Macrez N. Specificity of Gq and G11 protein signaling in vascular myocytes. Trends Cardiovasc Med 1998; 8:157-162.
35. Anand-Srivastava MB. Angiotensin II receptors negatively coupled to adenylate cyclase in rat aorta. Biochem Biophys Res Commun 1983; 117:420-428.
36. Ushio-Fukai M, Griendling KK, Akers M, Lyons PR, Alexander RW. Temporal dispersion of activation of phospholipase C-beta1 and-gamma isoforms by angiotensin II in vascular smooth muscle cells. Role of alphaq/11, alpha12, and beta gamma G protein subunits. J Biol Chem 1998; 273:19772-19777.
37. Anand-Srivastava MB. Angiotensin II receptors negatively coupled to adenylate cyclase in rat myocardial sarcolemma. Involvement of inhibitory guanine nucleotide regulatory protein. Biochem Pharmacol 1989; 38:489-496.
38. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98:322-334.
39. Fukata Y, Amano M, Kaibuki K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of nonmuscle cells. Trends Pharmacol Sci 2001; 22:32-39.
40. Calò L, Ceolotto G, Milani M, Pagnin E, van den Heuvel LP, Sartori M, et al. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int 2001; 60:882-889.
41. Calò L, Davis PA, Semplicini A. Reduced content of alpha subunit of Gq protein in monocytes of Bartter and Gitelman syndromes: relationship with vascular hyporeactivity. Kidney Int 2002; 61:353-354.
42. Di Virgilio F, Calò L, Cantaro S, Favaro S, Piccoli A, Borsatti A. Resting and stimulated cytosolic free calcium levels in neutrophils from patients with Bartter's syndrome. Clin Sci 1987; 72:483-488.
43. Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC, Calò LA. Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling. J Hypertens 2004; 22:1963-1969.
44. Calò L, Davis PA, Milani M, Cantaro S, Antonello A, Favaro S, et al. Increased endothelial nitric oxide synthase mRNA level in Bartter's and Gitelman's syndrome. Relationship to vascular reactivity. Clin Nephrol 1999; 51:12-17.
45. Calò L, D'Angelo A, Cantaro S, Bordin MC, Favaro S, Antonello A, et al. Increased urinary NO2-/NO3-and cyclic GMP levels in patients with Bartter's syndrome: relationship to vascular reactivity. Am J Kidney Dis 1996; 27:784-789.
46. Calò L, Cantaro S, Calabrò A, Piarulli F, Rizzolo M, Favaro S, et al. Endothelium-derived vasoactive substances in Bartter's syndrome. Angiology 1995; 46:905-913.
47. Calò LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E, et al. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. Nephrol Dial Transplant 2008; 23:2804-2809.
48. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3 kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004; 24:1842-1847.
49. Mita S, Kobayashi N, Yoshida K, Nakano S, Matsuoka H. Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J Hypertens 2005; 23:87-96.
50. Calò LA, Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC. Rho kinase inhibition and vascular protection: support from studies in Bartter and Gitelman syndrome. Arterioscler Thromb Vasc Biol 2005; 25:34-35.
51. Calò LA, Pagnin E, Sartori M, Semplicini A, Pessina AC. Bartter's and Gitelman's syndromes: a confirm in humans of the utility of Rho kinase inhibition for cardiovascular protection. J Hypertens 2005; 23:1273-1275.
52. Calò LA, Pagnin E, Davis PA, Sartori M, Semplicini A. Oxidative stress related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003; 18:1518-1525.
53. Calò LA, Facco M, Davis PA, Pagnin E, Maso LD, Puato M, et al. Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling. Hypertens Res 2011; 34:1017-1022.
54. Datla SR, Dusting GJ, Mori TA, Taylor CJ, Croft KD, Jiang F. Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress. Hypertension 2007; 50:636-642.
55. Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 2004; 279:8919-8929.
56. Wennerberg K, Der CJ. Rho-family GTPases: it's not only Rac and Rho (and I like it). J Cell Sci 2004; 117:1301-1312.
57. Siderovski DP, Willard FS. The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits. Int J Biol Sci 2005; 1:51-66.
58. Ying Z, Jin L, Dorrance AM, Webb RC. Increased expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. Am J Hypertens 2004; 17:981-985.
59. Wuertz MC, Lorincz A, Vettel C, Thomas MA, Wieland T, Lutz S. p63RhoGEF-a key mediator of angiotensin II dependent signaling and processes in vascular smooth muscle cells. FASEB J 2010; 24:4865-4876.
60. Momotani K, Artamonov MV, Utepbergenov D, Derewenda U, Derewenda ZS, Somlyo AV. p63RhoGEF couples Gaq/11-mediated signaling to Ca2+ sensitization of vascular smooth muscle contractility. Circ Res 2011; 109:993-1002.
61. Guilluy C, Brégeon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, Loufrani L, et al. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med 2010; 16:183-190.
62. Pagnin E, Semplicini A, Sartori M, Pessina AC, Calò LA. Reduced mRNA and protein content of Rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes: relevance for the pathophysiology of hypertension. Am J Hypertens 2005; 18:1200-1205.
63. Calò LA, Davis PA, Pagnin E, Dal Maso L, Maiolino G, Seccia TM, et al. Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients. Implications for vascular tone regulation and cardiovascular remodeling. J Hypertens 2014; 32:331-338.
64. Wirth A. Rho kinase and hypertension. Biochim Biophys Acta 2010; 1802:1276-1284.
65. Ross EM, Wilkie TM. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 2000; 69:795-827.
66. Hepler RJ. Emerging roles for RGS proteins in cell signalling. Trends Pharmacol Sci 1999; 20:376-382.
67. Zhong H, Neubig RR. Regulator of G protein signalling proteins; novel multifunctional drug targets. J Pharmacol Exp Ther 2001; 297:837-845.
68. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, et al. Hypertension and prolonged vasoconstrictor signalling in RGS2-deficient mice. J Clin Invest 2003; 111:445-452.
69. Tang M, Wang G, Lu P, Karas RH, Aronovitz M, Heximer SP, et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 2003; 9:1506-1512.
70. Li Y, Hashim S, Anand-Srivastava MB. Angiotensin II-evoked enhanced expression of RGS2 attenuates Gi-mediated adenylyl cyclase signaling in A10 cells. Cardiovasc Res 2005; 66:503-511.
71. Calò LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, et al. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 2004; 89:4153-4157.
72. Semplicini A, Lenzini L, Sartori M, Papparella I, Calò LA, Pagnin E, et al. Reduced expression of regulator of G protein signaling-2 in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens 2006; 24:1115-1124.
73. Calò LA, Pagnin E, Ceolotto G, Davis PA, Schiavo S, Papparella I, et al. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. J Hypertens 2008; 26:938-945.
74. Shankaranarayanan A, Thal DM, Tesmer VM, Roman DL, Neubig RR, Kozasa T, et al. Assembly of high order G alpha q-effector complexes with RGS proteins. J Biol Chem 2008; 283:34923-34934.
75. Baritono E, Ceolotto G, Papparella I, Sartori M, Ciccariello L, Iori E, et al. Abnormal regulation of G protein alpha(i2) subunit in skin fibroblasts from insulin-resistant hypertensive individuals. J Hypertens 2004; 22:783-792.
76. Stoff JS, Stemerman M, Steer M, Salzman E, Brown RS. A defect in platelet aggregation in Bartter's syndrome. Am J Med 1980; 68:171-180.
77. Touyz RM. Role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 2003; 5:155-164.
78. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part II. Animal and human studies. Circulation 2003; 108:2034-2040.
79. Griendling KK, Soresen D, Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res 2000; 86:494-501.
80. Calò L, Sartore G, Bassi A, Basso C, Bertocco S, Marin R, et al. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome). J Hypertens 1998; 16:1001-1008.
81. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25:1767-7175.
82. Budzyn K, Marley PD, Sobey CG. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci 2006; 27:97-104.
83. Sauzeau V, Rolli-Derkinderen M, Marionneau C, Loirand G, Pacaud P. RhoA expression is controlled by nitric oxide through cGMPdependent protein kinase activation. J Biol Chem 2003; 278:9472-9480.
84. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106:57-62.
85. Jin HG, Yamashita H, Nagano Y, Fukuba H, Hiji M, Ohtsuki T, et al. Hypoxia-induced upregulation of endothelial small G protein RhoA and Rho-kinase/ROCK2 inhibits eNOS expression. Neurosci Lett 2006; 408:62-67.
86. He WQ, Qiao YN, Zhang CH, Peng YJ, Chen C, Wang P, et al. Role of myosin light chain kinase in regulation of basal blood pressure and maintenance of salt-induced hypertension. Am J Physiol Heart Circ Physiol 2011; 301:H584-H591.
87. Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nat Rev Cardiol 2010; 7:637-647.
88. Shankaranarayanan A, Boguth CA, Lutz S, Vettel C, Uhlemann F, Aittaleb M, et al. Galpha q allosterically activates and relieves autoinhibition of p63RhoGEF. Cell Signal 2010; 22:1114-1123.
89. Calò LA, Montisci R, Scognamiglio R, Davis PA, Pagnin E, Schiavo S, et al. High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes). Are angiotensin II type 2 receptors involved? J Endocrinol Invest 2009; 32:832-836.
90. Savoia C, Tabet F, Yao G, Schiffrin EL, Touyz RM. Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens 2005; 23:1037-1045.
91. Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 2005; 45:840-844.
92. Siragy HM. Evidence for benefits of angiotensin receptor blockade beyond blood pressure control. Curr Hypertens Rep 2008; 10:261-267.
93. Undurti N. Das. Is angiotensin II an endogenous pro-inflammatory molecule? Med Sci Monit 2005; 11:155-162.
94. Alexander RW. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response, a new perspective. Hypertension 1995; 25:155-161.
95. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, et al. Angiotensin II is associated with activation of NFkB mediated genes and downregulation of PPARs. Physiol Genomics 2002; 11:21-31.
96. Davis PA, Mussap M, Pagnin E, Bertipaglia L, Savica V, Semplicini A, et al. Early markers of inflammation in a high angiotensin II state. Results of studies in Bartter's/Gitelman's syndromes. Nephrol Dial Transplant 2006; 21:1697-1701.
97. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, et al. Angiotensin II regulates the synthesis of proinflammatory cytokin22222222es and chemokines in the kidney. Kidney Int 2002; 62 (Suppl. 82):12-22.
98. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11:RA194-RA205.
99. Nakakuki T, Ito M, Iwasaki H, Kureishi Y, Okamoto R, Moriki N, et al. Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 2005; 25:2088-2093.
100. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997; 11:463-475.
101. Segain JP, Raingeard de la Bletiere D, Sauzeau V, Bourreille A, Hilaret G, Cario-Toumaniantz C, et al. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology 2003; 124:1180-1187.
102. Calò LA, Davis PA, Pagnin E, Schiavo S, Semplicini A, Pessina AC. Linking inflammation and hypertension in humans: studies in Bartter's/ Gitelman's syndromes. J Hum Hypertens 2008; 22:223-225.
103. Taniyama Y, Hitomi H, Shah A, Alexander RW, Griendling KK. Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler Thromb Vasc Biol 2005; 25:1142-1147.
104. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286:H1597-H1602.
105. Davis PA, Pagnin E, Semplicini A, Avogaro A, Calò LA. Insulin signaling, glucose metabolism and the angiotensin II signaling system Studies in Bartter's/Gitelman's syndromes. Diabetes Care 2006; 29:469-471.
106. Graiani G, Lagrasta C, Migliaccio E, Spillmann F, Meloni M, Madeddu P, et al. Genetic deletion of the p66Shc adaptor protein protects from angiotensin II-induced myocardial damage. Hypertension 2005; 46:433-440.
107. Avogaro A, Pagnin E, Calo L. Monocyte NADPH oxidase subunit p22(phox)and inducible hemeoxygenase-1 gene expressions are increased in type II diabetic patients: relationship with oxidative stress. J Clin Endocrinol Metab 2003; 88:1753-1759.
108. Pagnin E, Fadini G, de Toni R, Tiengo A, Calo L, Avogaro A. Diabetes induces p66shc gene expression in human peripheral blood mononuclear cells: relationship to oxidative stress. J Clin Endocrinol Metab 2005; 90:1130-1136.
109. Ingelfinger JR. Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. Curr Opin Nephrol Hypertens 2009; 18:79-84.
110. Yagil Y, Yagil C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension 2003; 41:871-873.
111. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43:970-976.
112. Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 2006; 168:1808-1820.
113. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417:822-828.
114. Ferreira AJ, Raizada MK. Are we poised to target ACE2 for the next generation of antihypertensives? J Mol Med 2008; 86:685-690.
115. Ferreira AJ, Santos RAS. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 2005; 38:499-507.
116. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 2006; 47:515-521.
117. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2003; 42:574-579.
118. Sampaio WO, Henrique De Castro C, Santos RAS, Schiffrin EL, Touyz RM. Angiotensin-(1-7) counterregulates angiotensin II in human endothelial cells. Hypertension 2007; 50:1093-1098.
119. Calò LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D'Angelo A, et al. ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications. J Nephrol 2010; 23:472-477.